[go: up one dir, main page]

WO1994003425A3 - Derives de carbostyrile pour le traitement de l'arythmie cardiaque - Google Patents

Derives de carbostyrile pour le traitement de l'arythmie cardiaque Download PDF

Info

Publication number
WO1994003425A3
WO1994003425A3 PCT/US1993/007050 US9307050W WO9403425A3 WO 1994003425 A3 WO1994003425 A3 WO 1994003425A3 US 9307050 W US9307050 W US 9307050W WO 9403425 A3 WO9403425 A3 WO 9403425A3
Authority
WO
WIPO (PCT)
Prior art keywords
lower alkyl
hydrogen
treatment
arrhythmia
carbostyril derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1993/007050
Other languages
English (en)
Other versions
WO1994003425A2 (fr
Inventor
Dominique Blondet
Jean-Claude Pascal
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Syntex USA LLC
Original Assignee
Syntex USA LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syntex USA LLC filed Critical Syntex USA LLC
Priority to AU47875/93A priority Critical patent/AU4787593A/en
Publication of WO1994003425A2 publication Critical patent/WO1994003425A2/fr
Publication of WO1994003425A3 publication Critical patent/WO1994003425A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/24—Oxygen atoms attached in position 8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/02—1,2-Thiazines; Hydrogenated 1,2-thiazines

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

L'invention se rapporte à des composés de la formule (I) dans laquelle m vaut 0, 1 ou 2; n vaut 0, 1 ou 2; R1 représente hydrogène, alkyle inférieur, ou alkyle inférieur phényle; R2 représente hydrogène, alkyle inférieur, trifluorométhyle, alcoxy inférieur, ou alcoxy inférieur phényle; R3 représente hydrogène, alkyle inférieur, trifluorométhyle, ou alcoxy inférieur; R4 représente hydrogène, alkyle inférieur, ou hydroxy, à condition que si R4 représente hydroxy, à la fois m et n valent 1; R5 représente hydrogène ou alkyle inférieur; R6 représente alkyle inférieur; W et Y représentent indépendamment -SO¿2?- ou -C(O)-; X représente oxygène, -S(O)p-, -CH2-, ou une liaison simple; où p vaut 0, 1 ou 2; et Z représente -CH=CH- ou -(CH2)q-, où q vaut 1 ou 2; ou un sel d'addition d'acide pharmaceutiquement acceptable, un ester ou N-oxyde de celui-ci. Ces composés sont utiles dans le traitement des maladies cardiovasculaires, notamment des arythmies.
PCT/US1993/007050 1992-07-31 1993-07-30 Derives de carbostyrile pour le traitement de l'arythmie cardiaque Ceased WO1994003425A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU47875/93A AU4787593A (en) 1992-07-31 1993-07-30 Heterocyclic derivatives useful in the treatment of cardiovascular diseases

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91769892A 1992-07-31 1992-07-31
US07/917,698 1992-07-31

Publications (2)

Publication Number Publication Date
WO1994003425A2 WO1994003425A2 (fr) 1994-02-17
WO1994003425A3 true WO1994003425A3 (fr) 1994-03-31

Family

ID=25439188

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1993/007050 Ceased WO1994003425A2 (fr) 1992-07-31 1993-07-30 Derives de carbostyrile pour le traitement de l'arythmie cardiaque

Country Status (4)

Country Link
AU (1) AU4787593A (fr)
IL (1) IL106549A0 (fr)
MX (1) MX9304626A (fr)
WO (1) WO1994003425A2 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5451677A (en) * 1993-02-09 1995-09-19 Merck & Co., Inc. Substituted phenyl sulfonamides as selective β 3 agonists for the treatment of diabetes and obesity
JPH09502166A (ja) * 1993-07-31 1997-03-04 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー アドレナリン受容体作動薬活性を有する２−ベンゾヘテロシクリルオキシまたはチオプロパノールアミン誘導体
US6075040A (en) * 1996-09-05 2000-06-13 Eli Lilly And Company Selective β3 adrenergic agonists
ZA967892B (en) * 1995-09-21 1998-03-18 Lilly Co Eli Selective β3 adrenergic agonists.
ES2179362T3 (es) * 1996-08-27 2003-01-16 Wyeth Corp Derivados de 4-aminoetoxi indolona.
US5817690A (en) * 1996-08-27 1998-10-06 American Home Products Corporation 4-aminoethoxy indolone derivatives
DE69711519T2 (de) 1996-09-05 2002-10-31 Eli Lilly And Co., Indianapolis Carbazolanaloge als selektive beta3-adrenergische Agonisten
CO5011072A1 (es) 1997-12-05 2001-02-28 Lilly Co Eli Etanolaminas pirazinil substituidas como agfonistas de los receptores
US6232337B1 (en) * 1997-12-05 2001-05-15 Eli Lilly And Company Selective β3 adrenergic agonists

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4081447A (en) * 1975-04-09 1978-03-28 Abbott Laboratories 5-[2-Hydroxy-3-(3,4-dimethoxy phenethylamino)]-propoxy-3,4-dihydro carbostyril and pharmaceutically acceptable salts thereof
US4642309A (en) * 1983-03-23 1987-02-10 Boehringer Mannheim Gmbh Indolin-2-one derivatives preparation thereof and intermediates for the preparation thereof
EP0245997A2 (fr) * 1986-05-01 1987-11-19 Pfizer Limited p-Aminoéthylsulfonanilides N-substitués comme agents antiarythmiques et intermédiaires
US5082847A (en) * 1990-07-18 1992-01-21 Syntex (U.S.A.) Inc. Carbostyril compounds connected via an oxyalkyl group with a piperidine ring and having pharmaceutical utility

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4081447A (en) * 1975-04-09 1978-03-28 Abbott Laboratories 5-[2-Hydroxy-3-(3,4-dimethoxy phenethylamino)]-propoxy-3,4-dihydro carbostyril and pharmaceutically acceptable salts thereof
US4642309A (en) * 1983-03-23 1987-02-10 Boehringer Mannheim Gmbh Indolin-2-one derivatives preparation thereof and intermediates for the preparation thereof
EP0245997A2 (fr) * 1986-05-01 1987-11-19 Pfizer Limited p-Aminoéthylsulfonanilides N-substitués comme agents antiarythmiques et intermédiaires
US5082847A (en) * 1990-07-18 1992-01-21 Syntex (U.S.A.) Inc. Carbostyril compounds connected via an oxyalkyl group with a piperidine ring and having pharmaceutical utility

Also Published As

Publication number Publication date
WO1994003425A2 (fr) 1994-02-17
MX9304626A (es) 1994-02-28
AU4787593A (en) 1994-03-03
IL106549A0 (en) 1993-12-08

Similar Documents

Publication Publication Date Title
NO180407C (no) Anvendelse av 1,3-oksatiolannukleosidanaloger ved fremstilling av et medikament for behandling av hepatitt B
ZA9410084B (en) Methods of inhibiting thrombin
AU1433588A (en) 1-phenyl-3-naphthalenyloxypropanamines
AU4497293A (en) Phenoxy- and phenoxyalkyl-piperidines as antiviral agents
HU9301197D0 (en) Medical preparatives containing quinoline and quinazoline derivatives as well as new quinoline and quinazoline derivatives
CA2102209A1 (fr) Nouveau derive de l'isoxazole et sel de ce dernier
AU7579194A (en) Methods for inhibiting angiogenisis and angiogenic diseases
IL114785A0 (en) Pyrrolocarbazoles their preparation and pharmaceutical compositions containing them
AU2868689A (en) Use of 1,4-disubstituted-piperidinyl compounds in the manufacture of a medicament for the treatment of insomnia
WO1994003425A3 (fr) Derives de carbostyrile pour le traitement de l'arythmie cardiaque
GR3005990T3 (fr)
DE69222459D1 (de) Thiazolidindionderivate, ihre Herstellung und Anwendung
AU1384788A (en) Method of improving sleep
EP0342587A3 (fr) Thiénotriazolodiazépines et leur applications pharmaceutiques
WO1986007059A3 (fr) Composes d'oxodiazine
CA2049655A1 (fr) Composition pharmaceutique pour inhiber l'aggregation des plaquettes
NO20003138L (no) Ny anvendelse av lokalanestetika mot vaskulære hodepiner
AU580162B2 (en) 1,3-oxathiane derivatives
EP0201349A3 (fr) Dérivés de tétrazole
ES8500955A1 (es) Procedimiento para la preparacion de furobenzoisoxazoles.
CA2187402A1 (fr) Derives de la quinoxaline pour le traitement des acouphenes
AU2532692A (en) Method for treating hypertension
EP0323604A3 (fr) Agent modifiant l'extensibilité veineuse et supprimant l'hypertrophie cardiaque renfermant un composé de la dihydropyridine
EP0272849A3 (en) Use of 2-oxo-imidazolidine derivatives in the treatment of kidney diseases
JPS5430192A (en) 2-(4-(2-hydroxyethyl)-1-piperazinylmethyl)-5-phenyloxazoles and their pharmaceutically permissible acid addition salt

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA FI HU JP KR NO NZ

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA FI HU JP KR NO NZ

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: CA

122 Ep: pct application non-entry in european phase